Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Unleashing the Power of Nitrazepam: A Comprehensive Review on R&D Breakthroughs, Action Mechanisms, and Drug Target
Drug Insights
4 min read
Unleashing the Power of Nitrazepam: A Comprehensive Review on R&D Breakthroughs, Action Mechanisms, and Drug Target
9 October 2023
This article summarized the latest R&D progress of Nitrazepam, the Mechanism of Action for Nitrazepam, and the drug target R&D trends for Nitrazepam.
Read →
MARIPOSA Phase 3 study hits key target, showing improved effectiveness of RYBREVANT® and Lazertinib versus Osimertinib for EGFR-Mut patients
Latest Hotspot
3 min read
MARIPOSA Phase 3 study hits key target, showing improved effectiveness of RYBREVANT® and Lazertinib versus Osimertinib for EGFR-Mut patients
9 October 2023
Landmark Phase 3 MARIPOSA Study achieves its main goal, demonstrating clinically relevant enhancement for RYBREVANT® and Lazertinib when compared to Osimertinib in EGFR-Mut patients.
Read →
A Comprehensive Review of Nimesulide's R&D Innovations and Drug Target Mechanism
Drug Insights
4 min read
A Comprehensive Review of Nimesulide's R&D Innovations and Drug Target Mechanism
9 October 2023
This article summarized the latest R&D progress of Nimesulide, the Mechanism of Action for Nimesulide, and the drug target R&D trends for Nimesulide.
Read →
Analysis on the Clinical Research Progress of Akt inhibitors
Analysis on the Clinical Research Progress of Akt inhibitors
9 October 2023
Akt, also known as protein kinase B, is a crucial enzyme that plays a significant role in various cellular processes within the human body.
Read →
Pharmaceutical Insights: Natamycin's R&D Progress and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Pharmaceutical Insights: Natamycin's R&D Progress and its Mechanism of Action on Drug Target
9 October 2023
This article summarized the latest R&D progress of Natamycin, the Mechanism of Action for Natamycin, and the drug target R&D trends for Natamycin.
Read →
Gracell Biotechnologies Announces Clinical Results for FasTCAR-T GC012F in High-Risk, Multiple Myeloma
Latest Hotspot
3 min read
Gracell Biotechnologies Announces Clinical Results for FasTCAR-T GC012F in High-Risk, Multiple Myeloma
9 October 2023
Gracell Biotechnologies has showcased updated long-term data from a continuing Phase 1 trial. This trial is assessing GC012F, a candidate for autologous CAR-T treatment that simultaneously targets CD19 and the B-cell maturation antigen (BCMA).
Read →
Exploring Moxidectine's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Exploring Moxidectine's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
9 October 2023
This article summarized the latest R&D progress of Moxidectine, the Mechanism of Action for Moxidectine, and the drug target R&D trends for Moxidectine.
Read →
Analysis on the Research Progress of Biosimilar Drugs
Advanced Tech.
5 min read
Analysis on the Research Progress of Biosimilar Drugs
9 October 2023
Biosimilar drugs: These are therapeutic biological products that have similarity in quality, safety, and efficacy with a previously registered reference drug.
Read →
Decoding Lurbinectedin: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
Drug Insights
4 min read
Decoding Lurbinectedin: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
9 October 2023
This article summarized the latest R&D progress of Lurbinectedin, the Mechanism of Action for Lurbinectedin, and the drug target R&D trends for Lurbinectedin.
Read →
Elicio Therapeutics Showcases Findings from the initial Phase of the ELI-002 Study
Latest Hotspot
3 min read
Elicio Therapeutics Showcases Findings from the initial Phase of the ELI-002 Study
9 October 2023
Elicio Therapeutics has revealed encouraging initial data related to relapse-free survival from their ongoing Phase 1 investigation of their primary asset, ELI-002.
Read →
Deep Scientific Insights on Lidocaine hydrochloride's R&D Progress, Mechanism of Action, and Drug Target
Drug Insights
4 min read
Deep Scientific Insights on Lidocaine hydrochloride's R&D Progress, Mechanism of Action, and Drug Target
8 October 2023
This article summarized the latest R&D progress of Lidocaine hydrochloride, the Mechanism of Action for Lidocaine hydrochloride, and the drug target R&D trends for Lidocaine hydrochloride.
Read →
Harpoon Therapeutics Unveils Initial Phase 1 Results of HPN217 at IMS Yearly Conference
Latest Hotspot
3 min read
Harpoon Therapeutics Unveils Initial Phase 1 Results of HPN217 at IMS Yearly Conference
8 October 2023
Harpoon Therapeutics, Inc. has shared the interim outcomes of its Phase 1 clinical trial on the effect of single-agent HPN217 in treating relapsed or refractory multiple myeloma, focused on target dose groups from 2.15 to 12mg.
Read →